Pharmacoeconomic review report: Cladribine (Mavenclad) (EMD Serono) indication : as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability
Cladribine (Mavenclad) is indicated as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability. It is administered orally and is available as a 10 mg tablet at a price...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, October 2018
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Cladribine (Mavenclad) is indicated as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability. It is administered orally and is available as a 10 mg tablet at a price of $3,082.70 per tablet. The recommended cumulative dose is 3.5 mg/kg over the course of two years, with one treatment course of 1.75 mg/kg per year. The treatment course is spread over two weeks each year, one week at the beginning of the first month of that year, and the other at the beginning of the second month. During each week, patients receive one or two 10 mg tablets, based on body weight, over the course of four to five days. The average annual cost is $43,158 based on patient weight of 70 kg. The manufacturer submitted a cost-utility analysis based on a Markov state-transition model comparing cladribine with other available disease-modifying therapies (DMTs) |
|---|---|
| Item Description: | "Version: Final with redactions." |
| Physical Description: | 1 PDF file (33 pages) illustrations |